FDA Announces Food Safety Reinspection Fees to Ruin Your 2027 Budget
Published Date: 7/30/2026
Notice
Summary
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 fee rates for certain domestic and foreign facility reinspections, failures to comply with a recall order, and importer reinspections that are authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA).
Analyzed Economic Effects
4 provisions identified: 1 benefits, 3 costs, 0 mixed.
FY2027 FSMA Hourly Fee Rates
For FY2027, FDA set the hourly rates used to bill for reinspections and related activities at $354 per hour when domestic travel is required and $414 per hour when foreign travel is required. These rates apply from October 1, 2026 through September 30, 2027 and will be used to calculate fees billed to responsible parties, U.S. agents, and importers.
Who Triggers FSMA Fees
FDA will assess fees when: (1) a domestic or foreign facility is reinspected after an initial inspection had a final classification of Official Action Indicated (OAI) for noncompliance materially related to food safety, and (2) an importer or responsible party fails to comply with a recall order. Fees are billed based on the number of direct hours spent on the reinspection or recall-related activities, charged at the hourly rates in the FY2027 fee schedule.
Payment Terms and Collections
FDA will send an invoice after it completes the billed work and payments must be made within 30 days of the invoice date in U.S. currency by electronic check (ACH/eCheck), credit card, or wire transfer. Credit card payments are only accepted for balances under $25,000; unpaid fees will be treated as a U.S. Government claim and may be referred to collections.
Small Business Fee Reduction Consideration
FDA says it recognizes that full cost recovery could impose severe hardship on small businesses and intends to consider reducing certain fees for those firms. FDA also states it does not intend to issue invoices for reinspection or recall order fees until it publishes separate guidance describing how firms may request a fee reduction.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-15335, Medical Device User Fee Rates for Fiscal Year 2027
Starting October 1, 2026, medical device companies will see updated user fees for submitting their products to the FDA and for annual registrations. These fees help the FDA review and monitor medical devices, with special discounts available for small businesses. If you’re in the medical device world, get ready to budget for these new costs through September 30, 2027!
Next: 2026-15337, Food Safety Modernization Act Third-Party Certification Program User Fee Rate for Fiscal Year 2027
The Food and Drug Administration (FDA or we) is announcing the fiscal year (FY) 2027 annual fee rate for recognized accreditation bodies and accredited certification bodies, and the initial and renewal fee rate for accreditation bodies applying to be recognized in the third-party certification program authorized by the Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the FDA Food Safety Modernization Act (FSMA). We are also announcing the fee rate for certification bodies applying for direct FDA accreditation.